The study is designed to assess whether the addition of SCIB1 treatment will result in an improvement in the tumour response rate.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.